Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Incyte
Biotech
Hemab CEO seeks ‘flavor of a multi-product coagulation company’
With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
Will Maddox
Aug 13, 2026 9:00am
Incyte ditches phase 1-stage JAK inhibitor for next-gen options
Jul 28, 2026 10:32am
Lilly’s $2.3B Ajax drug works ‘right out of the gate’
Jun 13, 2026 11:15am
Incyte inks $2B deal to add Star biz to late-phase constellation
Jun 8, 2026 9:07am
Incyte pays Genesis $80M to expand AI-fueled drug discovery pact
May 20, 2026 10:22am
Incyte inks deal with Edison to train AI through drug discovery
May 19, 2026 10:30am
